Global Swine Vaccines Market Size, Share, Trends & Growth Analysis Report 2026-2034

Description

The Swine Vaccines Market size is expected to reach USD 3.69 Billion in 2034 from USD 2.28 Billion (2025) growing at a CAGR of 5.49% during 2026-2034.

The swine vaccines market is set for robust growth, driven by the increasing prevalence of infectious diseases affecting pig populations. As the global demand for pork continues to rise, the need for effective vaccination strategies to ensure herd health and productivity becomes paramount. The emergence of novel pathogens and the resurgence of previously controlled diseases necessitate ongoing research and development in vaccine formulations. Companies are investing heavily in innovative technologies, such as recombinant vaccines and mRNA-based solutions, which promise enhanced efficacy and safety profiles, thereby addressing the evolving challenges faced by swine producers.

Moreover, the growing awareness of biosecurity measures among livestock farmers is significantly influencing the swine vaccines market. Producers are increasingly recognizing the importance of vaccination as a critical component of comprehensive herd management strategies. This shift in mindset is fostering a proactive approach to disease prevention, leading to higher vaccination rates and, consequently, a more resilient swine population. The integration of digital tools for monitoring and managing vaccination schedules is also gaining traction, enabling farmers to optimize their herd health management practices and improve overall productivity.

Additionally, the expansion of the global swine industry, particularly in emerging markets, presents lucrative opportunities for the swine vaccines market. As countries strive to enhance their livestock production capabilities to meet growing consumer demand, the adoption of advanced vaccination programs becomes essential. Collaborations between vaccine manufacturers and agricultural organizations are expected to facilitate knowledge transfer and improve access to vaccination technologies in these regions. The future of the swine vaccines market appears promising, characterized by continuous innovation, increased awareness of disease management, and a commitment to enhancing animal health and welfare.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product

Inactivated vaccines
Live attenuated vaccines
Recombinant vaccines
Subunit vaccines
Toxoid vaccines
Other products

By Disease Type

Porcine reproductive and respiratory syndrome (PRRS)
Porcine circovirus type 2 (PCV2)
Mycoplasma hyopneumoniae
Classical swine fever (CSF)
Swine influenza
Erysipelas
Foot-and-Mouth disease (FMD)
African swine fever (ASF)
Porcine parvovirus
Other disease types

By End-user

Veterinary hospitals & clinics
Swine farms
Research institutes

COMPANIES PROFILED

Biogenesis Bago, Bioveta, Boehringer Ingelheim International GmbH, Ceva Sant Animale, Elanco Animal Health Incorporated, HIPRA, Indian Immunologicals Limited, Merck Co Inc, Phibro Animal Health Corporation, Vaxxinova, Virbac, Zoetis Inc

We can customise the report as per your requriements

Product Code: VMR11214069

Chapter 1. PREFACE

1.1. Market Segmentation & Scope
1.2. Market Definition
1.3. Information Procurement
- 1.3.1 Information Analysis
- 1.3.2 Market Formulation & Data Visualization
- 1.3.3 Data Validation & Publishing
1.4. Research Scope and Assumptions
- 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

2.1. Market Snapshot
2.2. Segmental Outlook
2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

3.1. Market Lineage Outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Value Chain Analysis
3.4. Regulatory Framework
- 3.4.1 Standards & Compliance
- 3.4.2 Regulatory Impact Analysis
3.5. Market Dynamics
- 3.5.1 Market Drivers
- 3.5.2 Market Restraints
- 3.5.3 Market Opportunities
- 3.5.4 Market Challenges
3.6. Porter's Five Forces Analysis
3.7. PESTLE Analysis

Chapter 4. GLOBAL SWINE VACCINES MARKET: BY PRODUCT 2022-2034 (USD MN and Million Doses)

4.1. Market Analysis, Insights and Forecast Product
4.2. Inactivated vaccines Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
4.3. Live attenuated vaccines Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
4.4. Recombinant vaccines Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
4.5. Subunit vaccines Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
4.6. Toxoid vaccines Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
4.7. Other products Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 5. GLOBAL SWINE VACCINES MARKET: BY DISEASE TYPE 2022-2034 (USD MN and Million Doses)

5.1. Market Analysis, Insights and Forecast Disease Type
5.2. Porcine reproductive and respiratory syndrome (PRRS) Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
5.3. Porcine circovirus type 2 (PCV2) Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
5.4. Mycoplasma hyopneumoniae Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
5.5. Classical swine fever (CSF) Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
5.6. Swine influenza Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
5.7. Erysipelas Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
5.8. Foot-and-Mouth disease (FMD) Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
5.9. African swine fever (ASF) Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
5.10. Porcine parvovirus Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
5.11. Other disease types Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 6. GLOBAL SWINE VACCINES MARKET: BY END-USER 2022-2034 (USD MN and Million Doses)

6.1. Market Analysis, Insights and Forecast End-user
6.2. Veterinary hospitals & clinics Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
6.3. Swine farms Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
6.4. Research institutes Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 7. GLOBAL SWINE VACCINES MARKET: BY REGION 2022-2034(USD MN and Million Doses)

7.1. Regional Outlook
7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
- 7.2.1 By Product
- 7.2.2 By Disease Type
- 7.2.3 By End-user
- 7.2.4 United States
- 7.2.5 Canada
- 7.2.6 Mexico
7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
- 7.3.1 By Product
- 7.3.2 By Disease Type
- 7.3.3 By End-user
- 7.3.4 United Kingdom
- 7.3.5 France
- 7.3.6 Germany
- 7.3.7 Italy
- 7.3.8 Russia
- 7.3.9 Rest Of Europe
7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
- 7.4.1 By Product
- 7.4.2 By Disease Type
- 7.4.3 By End-user
- 7.4.4 India
- 7.4.5 Japan
- 7.4.6 South Korea
- 7.4.7 Australia
- 7.4.8 South East Asia
- 7.4.9 Rest Of Asia Pacific
7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
- 7.5.1 By Product
- 7.5.2 By Disease Type
- 7.5.3 By End-user
- 7.5.4 Brazil
- 7.5.5 Argentina
- 7.5.6 Peru
- 7.5.7 Chile
- 7.5.8 South East Asia
- 7.5.9 Rest of Latin America
7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
- 7.6.1 By Product
- 7.6.2 By Disease Type
- 7.6.3 By End-user
- 7.6.4 Saudi Arabia
- 7.6.5 UAE
- 7.6.6 Israel
- 7.6.7 South Africa
- 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

8.1. Recent Developments
8.2. Company Categorization
8.3. Supply Chain & Channel Partners (based on availability)
8.4. Market Share & Positioning Analysis (based on availability)
8.5. Vendor Landscape (based on availability)
8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL SWINE VACCINES INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Company Profiles
- 9.2.1 Biogenesis Bago
- 9.2.2 Bioveta
- 9.2.3 Boehringer Ingelheim International GmbH
- 9.2.4 Ceva SantAfA(C) Animale
- 9.2.5 Elanco Animal Health Incorporated
- 9.2.6 HIPRA
- 9.2.7 Indian Immunologicals Limited
- 9.2.8 Merck & Co. Inc
- 9.2.9 Phibro Animal Health Corporation
- 9.2.10 Vaxxinova
- 9.2.11 Virbac
- 9.2.12 Zoetis Inc